Does the media refer more to SANA or BCYC?

In the previous week, Sana Biotechnology had 4 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 6 mentions for Sana Biotechnology and 2 mentions for Bicycle Therapeutics. Sana Biotechnology's average media sentiment score of 0.79 beat Bicycle Therapeutics' score of 0.25 indicating that Sana Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicycle Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to KURA or BCYC?

In the previous week, Kura Oncology had 4 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 6 mentions for Kura Oncology and 2 mentions for Bicycle Therapeutics. Kura Oncology's average media sentiment score of 1.00 beat Bicycle Therapeutics' score of 0.25 indicating that Kura Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicycle Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BCYC or JANX?

In the previous week, Janux Therapeutics had 2 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 4 mentions for Janux Therapeutics and 2 mentions for Bicycle Therapeutics. Janux Therapeutics' average media sentiment score of 1.34 beat Bicycle Therapeutics' score of 0.25 indicating that Janux Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicycle Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Janux Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SVRA or BCYC?

In the previous week, Savara had 1 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 3 mentions for Savara and 2 mentions for Bicycle Therapeutics. Savara's average media sentiment score of 1.43 beat Bicycle Therapeutics' score of 0.25 indicating that Savara is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicycle Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate BCYC or CVAC?

Bicycle Therapeutics currently has a consensus price target of $13.86, suggesting a potential upside of 226.82%. Given Bicycle Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Bicycle Therapeutics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicycle Therapeutics 1 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.44 CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Bicycle Therapeutics (BCYC) Competitors

$4.24 -0.06 (-1.40%)

As of 04:00 PM Eastern

Compare

BCYC vs. SANA, KURA, JANX, SVRA, and CVAC

Should you buy Bicycle Therapeutics stock or one of its competitors? Bicycle Therapeutics's main competitors and comparable companies include Sana Biotechnology (SANA), Kura Oncology (KURA), Janux Therapeutics (JANX), Savara (SVRA), and CureVac (CVAC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Bicycle Therapeutics compare to Sana Biotechnology?

Sana Biotechnology (NASDAQ:SANA) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

Sana Biotechnology has a beta of 2.12, meaning that its stock price is 112% more volatile than the broader market. Comparatively, Bicycle Therapeutics has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market.

In the previous week, Sana Biotechnology had 4 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 6 mentions for Sana Biotechnology and 2 mentions for Bicycle Therapeutics. Sana Biotechnology's average media sentiment score of 0.79 beat Bicycle Therapeutics' score of 0.25 indicating that Sana Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bicycle Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

88.2% of Sana Biotechnology shares are held by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are held by institutional investors. 25.4% of Sana Biotechnology shares are held by company insiders. Comparatively, 22.0% of Bicycle Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Bicycle Therapeutics has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A
Bicycle Therapeutics	$72.86M	4.07	-$218.96M	-$2.73	N/A

Sana Biotechnology has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -311.11%. Bicycle Therapeutics' return on equity of -33.22% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-103.02%	-39.16%
Bicycle Therapeutics	-311.11%	-33.22%	-27.79%

Sana Biotechnology presently has a consensus price target of $9.33, indicating a potential upside of 138.10%. Bicycle Therapeutics has a consensus price target of $13.86, indicating a potential upside of 226.82%. Given Bicycle Therapeutics' higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than Sana Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

Summary

Sana Biotechnology beats Bicycle Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Bicycle Therapeutics compare to Kura Oncology?

Kura Oncology (NASDAQ:KURA) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

Kura Oncology has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, Bicycle Therapeutics has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market.

Bicycle Therapeutics has a net margin of -311.11% compared to Kura Oncology's net margin of -384.30%. Bicycle Therapeutics' return on equity of -33.22% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-384.30%	-207.18%	-45.17%
Bicycle Therapeutics	-311.11%	-33.22%	-27.79%

86.2% of Bicycle Therapeutics shares are held by institutional investors. 7.6% of Kura Oncology shares are held by insiders. Comparatively, 22.0% of Bicycle Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Kura Oncology currently has a consensus price target of $25.40, suggesting a potential upside of 93.16%. Bicycle Therapeutics has a consensus price target of $13.86, suggesting a potential upside of 226.82%. Given Bicycle Therapeutics' higher possible upside, analysts plainly believe Bicycle Therapeutics is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

Bicycle Therapeutics has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	17.34	-$278.67M	-$3.37	N/A
Bicycle Therapeutics	$72.86M	4.07	-$218.96M	-$2.73	N/A

In the previous week, Kura Oncology had 4 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 6 mentions for Kura Oncology and 2 mentions for Bicycle Therapeutics. Kura Oncology's average media sentiment score of 1.00 beat Bicycle Therapeutics' score of 0.25 indicating that Kura Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bicycle Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Bicycle Therapeutics beats Kura Oncology on 11 of the 16 factors compared between the two stocks.

How does Bicycle Therapeutics compare to Janux Therapeutics?

Bicycle Therapeutics (NASDAQ:BCYC) and Janux Therapeutics (NASDAQ:JANX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

Janux Therapeutics has lower revenue, but higher earnings than Bicycle Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	4.07	-$218.96M	-$2.73	N/A
Janux Therapeutics	$10M	121.06	-$113.62M	-$1.64	N/A

86.2% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are owned by institutional investors. 22.0% of Bicycle Therapeutics shares are owned by company insiders. Comparatively, 7.9% of Janux Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Bicycle Therapeutics presently has a consensus target price of $13.86, indicating a potential upside of 226.82%. Janux Therapeutics has a consensus target price of $36.46, indicating a potential upside of 84.15%. Given Bicycle Therapeutics' higher probable upside, research analysts plainly believe Bicycle Therapeutics is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67

Janux Therapeutics has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -311.11%. Janux Therapeutics' return on equity of -11.89% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-311.11%	-33.22%	-27.79%
Janux Therapeutics	N/A	-11.89%	-11.13%

In the previous week, Janux Therapeutics had 2 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 4 mentions for Janux Therapeutics and 2 mentions for Bicycle Therapeutics. Janux Therapeutics' average media sentiment score of 1.34 beat Bicycle Therapeutics' score of 0.25 indicating that Janux Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicycle Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Janux Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bicycle Therapeutics has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.53, meaning that its stock price is 153% more volatile than the broader market.

Summary

Janux Therapeutics beats Bicycle Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Bicycle Therapeutics compare to Savara?

Savara (NASDAQ:SVRA) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

87.9% of Savara shares are held by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are held by institutional investors. 5.3% of Savara shares are held by company insiders. Comparatively, 22.0% of Bicycle Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Savara has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market. Comparatively, Bicycle Therapeutics has a beta of 1.54, meaning that its share price is 54% more volatile than the broader market.

Savara has higher earnings, but lower revenue than Bicycle Therapeutics. Savara is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.58	N/A
Bicycle Therapeutics	$72.86M	4.07	-$218.96M	-$2.73	N/A

Savara presently has a consensus price target of $10.14, suggesting a potential upside of 88.88%. Bicycle Therapeutics has a consensus price target of $13.86, suggesting a potential upside of 226.82%. Given Bicycle Therapeutics' higher probable upside, analysts clearly believe Bicycle Therapeutics is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

Savara has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -311.11%. Bicycle Therapeutics' return on equity of -33.22% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-90.28%	-68.95%
Bicycle Therapeutics	-311.11%	-33.22%	-27.79%

In the previous week, Savara had 1 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 3 mentions for Savara and 2 mentions for Bicycle Therapeutics. Savara's average media sentiment score of 1.43 beat Bicycle Therapeutics' score of 0.25 indicating that Savara is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bicycle Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Savara beats Bicycle Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Bicycle Therapeutics compare to CureVac?

Bicycle Therapeutics (NASDAQ:BCYC) and CureVac (NASDAQ:CVAC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

86.2% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 22.0% of Bicycle Therapeutics shares are owned by company insiders. Comparatively, 2.2% of CureVac shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Bicycle Therapeutics currently has a consensus price target of $13.86, suggesting a potential upside of 226.82%. Given Bicycle Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Bicycle Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CureVac has lower revenue, but higher earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	4.07	-$218.96M	-$2.73	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

Bicycle Therapeutics has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market. Comparatively, CureVac has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market.

CureVac has a net margin of 199.92% compared to Bicycle Therapeutics' net margin of -311.11%. CureVac's return on equity of -23.03% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-311.11%	-33.22%	-27.79%
CureVac	199.92%	-23.03%	-19.09%

In the previous week, Bicycle Therapeutics had 2 more articles in the media than CureVac. MarketBeat recorded 2 mentions for Bicycle Therapeutics and 0 mentions for CureVac. Bicycle Therapeutics' average media sentiment score of 0.25 beat CureVac's score of 0.00 indicating that Bicycle Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Bicycle Therapeutics	Neutral
CureVac	Neutral

Summary

Bicycle Therapeutics and CureVac tied by winning 8 of the 16 factors compared between the two stocks.

Get Bicycle Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCYC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCYC vs. The Competition

Export

Metric	Bicycle Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$300.97M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-1.55	12.66	273.28	25.38
Price / Sales	4.07	1,309.16	613.48	92.60
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	0.58	16.29	12.89	6.14
Net Income	-$218.96M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-2.08%	-1.37%	-0.33%	-1.47%
1 Month Performance	9.56%	11.07%	6.51%	2.47%
1 Year Performance	-40.28%	53.71%	25.19%	15.84%

Bicycle Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCYC Bicycle Therapeutics	1.9935 of 5 stars	$4.24 -1.4%	$13.86 +226.8%	-40.3%	$300.97M	$72.86M	N/A	240	News Coverage
SANA Sana Biotechnology	2.4081 of 5 stars	$3.82 -1.4%	$9.33 +144.6%	+37.0%	$1.14B	N/A	N/A	380
KURA Kura Oncology	3.7678 of 5 stars	$12.75 +0.8%	$25.40 +99.2%	+64.9%	$1.13B	$67.48M	N/A	130	Positive News
JANX Janux Therapeutics	2.4997 of 5 stars	$18.36 +0.8%	$36.46 +98.6%	-13.8%	$1.12B	$10M	N/A	30
SVRA Savara	2.214 of 5 stars	$5.35 -0.8%	$10.14 +89.6%	+65.0%	$1.10B	N/A	N/A	20	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCYC) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bicycle Therapeutics (BCYC) Competitors

BCYC vs. SANA, KURA, JANX, SVRA, and CVAC

How does Bicycle Therapeutics compare to Sana Biotechnology?

Summary

How does Bicycle Therapeutics compare to Kura Oncology?

Summary

How does Bicycle Therapeutics compare to Janux Therapeutics?

Summary

How does Bicycle Therapeutics compare to Savara?

Summary

How does Bicycle Therapeutics compare to CureVac?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCYC vs. The Competition

Bicycle Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bicycle Therapeutics (BCYC) Competitors

BCYC vs. SANA, KURA, JANX, SVRA, and CVAC

How does Bicycle Therapeutics compare to Sana Biotechnology?

Which has more risk & volatility, SANA or BCYC?

Does the media refer more to SANA or BCYC?

Do institutionals & insiders believe in SANA or BCYC?

Which has higher valuation & earnings, SANA or BCYC?

Is SANA or BCYC more profitable?

Do analysts rate SANA or BCYC?

Summary

How does Bicycle Therapeutics compare to Kura Oncology?

Which has more volatility & risk, KURA or BCYC?

Is KURA or BCYC more profitable?

Do institutionals & insiders hold more shares of KURA or BCYC?

Do analysts recommend KURA or BCYC?

Which has preferable earnings & valuation, KURA or BCYC?

Does the media refer more to KURA or BCYC?

Summary

How does Bicycle Therapeutics compare to Janux Therapeutics?

Which has stronger earnings and valuation, BCYC or JANX?

Do institutionals & insiders have more ownership in BCYC or JANX?

Do analysts prefer BCYC or JANX?

Is BCYC or JANX more profitable?

Does the media favor BCYC or JANX?

Which has more risk & volatility, BCYC or JANX?

Summary

How does Bicycle Therapeutics compare to Savara?

Do institutionals & insiders hold more shares of SVRA or BCYC?

Which has more risk and volatility, SVRA or BCYC?

Which has stronger valuation and earnings, SVRA or BCYC?

Do analysts recommend SVRA or BCYC?

Is SVRA or BCYC more profitable?

Does the media refer more to SVRA or BCYC?

Summary

How does Bicycle Therapeutics compare to CureVac?

Do institutionals and insiders hold more shares of BCYC or CVAC?

Do analysts rate BCYC or CVAC?

Which has higher earnings and valuation, BCYC or CVAC?

Which has more risk and volatility, BCYC or CVAC?

Is BCYC or CVAC more profitable?

Does the media favor BCYC or CVAC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCYC vs. The Competition

Bicycle Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools